Silexion Therapeutics Corp

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

SLXN$0.11-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows (unaudited)

	Nine months ended September 30,		Three months ended September 30
	2024	2023	2024	2023
U.S. dollars in thousands · U.S. dollars in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(14,772)	$(3,428)	$(11,860)	$(809)
Adjustments required to reconcile loss to net cash used in operating activities:
Depreciation	37	39	22	10
Share-based compensation expenses	5,862	96	5,798	32
Non-cash financial expenses	3,968	365	3,749	108
Gain on disposal of property and equipment	-	(1)	-	(1)
Loss from lease termination	68	-	68	-
Changes in operating assets and liabilities:
Increase (decrease) in prepaid expenses	(609)	(200)	(417)	(198)
Increase (decrease) in other receivables	(59)	15	(17)	24
Increase (decrease) in trade payable	479	74	517	131
Net change in operating lease	(40)	(7)	(44)	(2)
Increase (decrease) in employee related obligations	480	(75)	436	(13)
Increase (decrease) in accrued expenses	(884)	(150)	(905)	33
Net cash used in operating activities	(5,470)	(3,272)	(2,653)	(685)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from short-term deposit	-	507	-	-
Purchase of property and equipment	(22)	(8)	(16)	(6)
Proceeds from Sale of property and equipment	-	78	-	78
Net cash provided by (used in) investing activities	(22)	577	(16)	72
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of preferred shares and warrants, net of issuance costs	-	522	-	-
Proceeds from issuance of ordinary shares (ELOC)	620	-	620	-
Cash received from Transactions upon the effectiveness of the SPAC Merger	2,300	-	2,300	-
Net cash provided by financing activities	2,920	522	2,920	-
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(2,572)	(2,173)	251	(613)
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(50)	(324)	25	(66)
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD	4,645	8,309	1,747	6,491
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD	2,023	$5,812	2,023	5,812

F - 9

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine months ended September 30, · Three months ended September 30
2024 · 2023 · 2024 · 2023
U.S. dollars in thousands · U.S. dollars in thousands
Appendix A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents	1,973		5,764		1,973		5,764
Restricted cash	50		48		50		48
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS	$2023		$5,812		$2023		$5,812
Appendix B - SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Operating lease termination	$(55)	$	-		$(55)	$	-
Conversion of preferred shares	$15,058	$	-		$15,058	$	-
Conversion of warrants to preferred shares on a cashless basis	$334	$	-		$334	$	-
Conversion of non-controlling interests	$3,344	$	-		$3,344	$	-
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest received	$25		$120	$	-		$42

F - 10

SILEXION LTD.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.